The estimated cumulative risk of developing serous carcinoma is lowest in the BRAF-mutated group, with the 10-year risk being 0.5% compared to 4.4% for wildtype and 2.3% for KRAS-mutated SBTs (Figure 2). Here, KRAS is linked to serous adenocarcinoma.